Logo image of FTRE

FORTREA HOLDINGS INC (FTRE) Stock Fundamental Analysis

USA - NASDAQ:FTRE - US34965K1079 - Common Stock

10.13 USD
-0.52 (-4.88%)
Last: 9/19/2025, 6:44:39 PM
10.13 USD
0 (0%)
After Hours: 9/19/2025, 6:44:39 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to FTRE. FTRE was compared to 55 industry peers in the Life Sciences Tools & Services industry. Both the profitability and financial health of FTRE have multiple concerns. FTRE has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

FTRE had positive earnings in the past year.
FTRE had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: FTRE reported negative net income in multiple years.
In the past 5 years FTRE always reported a positive cash flow from operatings.
FTRE Yearly Net Income VS EBIT VS OCF VS FCFFTRE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 200M -200M

1.2 Ratios

FTRE has a Return On Assets of -36.22%. This is amonst the worse of the industry: FTRE underperforms 80.00% of its industry peers.
FTRE's Return On Equity of -174.29% is on the low side compared to the rest of the industry. FTRE is outperformed by 87.27% of its industry peers.
Industry RankSector Rank
ROA -36.22%
ROE -174.29%
ROIC N/A
ROA(3y)-1.75%
ROA(5y)-2.26%
ROE(3y)-6.6%
ROE(5y)-5.54%
ROIC(3y)N/A
ROIC(5y)N/A
FTRE Yearly ROA, ROE, ROICFTRE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -10 -20

1.3 Margins

The Gross Margin of FTRE (19.73%) is worse than 83.64% of its industry peers.
FTRE's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for FTRE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 19.73%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.07%
GM growth 5YN/A
FTRE Yearly Profit, Operating, Gross MarginsFTRE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 10 -10 20

More info and screens

1

2. Health

2.1 Basic Checks

FTRE does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for FTRE has been increased compared to 1 year ago.
FTRE has a better debt/assets ratio than last year.
FTRE Yearly Shares OutstandingFTRE Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 20M 40M 60M 80M
FTRE Yearly Total Debt VS Total AssetsFTRE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 1B 2B 3B 4B

2.2 Solvency

FTRE has an Altman-Z score of 0.49. This is a bad value and indicates that FTRE is not financially healthy and even has some risk of bankruptcy.
FTRE's Altman-Z score of 0.49 is on the low side compared to the rest of the industry. FTRE is outperformed by 67.27% of its industry peers.
A Debt/Equity ratio of 1.87 is on the high side and indicates that FTRE has dependencies on debt financing.
With a Debt to Equity ratio value of 1.87, FTRE is not doing good in the industry: 83.64% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.87
Debt/FCF N/A
Altman-Z 0.49
ROIC/WACCN/A
WACC10.14%
FTRE Yearly LT Debt VS Equity VS FCFFTRE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 1B 2B 3B

2.3 Liquidity

FTRE has a Current Ratio of 1.02. This is a normal value and indicates that FTRE is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.02, FTRE is doing worse than 87.27% of the companies in the same industry.
FTRE has a Quick Ratio of 1.02. This is a normal value and indicates that FTRE is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of FTRE (1.02) is worse than 81.82% of its industry peers.
Industry RankSector Rank
Current Ratio 1.02
Quick Ratio 1.02
FTRE Yearly Current Assets VS Current LiabilitesFTRE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 72.22% over the past year.
Looking at the last year, FTRE shows a decrease in Revenue. The Revenue has decreased by -4.96% in the last year.
Measured over the past years, FTRE shows a decrease in Revenue. The Revenue has been decreasing by -4.10% on average per year.
EPS 1Y (TTM)72.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%733.33%
Revenue 1Y (TTM)-4.96%
Revenue growth 3Y-4.1%
Revenue growth 5YN/A
Sales Q2Q%7.23%

3.2 Future

The Earnings Per Share is expected to grow by 42.19% on average over the next years. This is a very strong growth
Based on estimates for the next years, FTRE will show a small growth in Revenue. The Revenue will grow by 1.53% on average per year.
EPS Next Y68.93%
EPS Next 2Y64.76%
EPS Next 3Y53.01%
EPS Next 5Y42.19%
Revenue Next Year-2.61%
Revenue Next 2Y-1.44%
Revenue Next 3Y0%
Revenue Next 5Y1.53%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
FTRE Yearly Revenue VS EstimatesFTRE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B
FTRE Yearly EPS VS EstimatesFTRE Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1 2 3

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

FTRE is valuated correctly with a Price/Earnings ratio of 16.34.
Based on the Price/Earnings ratio, FTRE is valued cheaper than 89.09% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 27.38. FTRE is valued slightly cheaper when compared to this.
The Price/Forward Earnings ratio is 10.97, which indicates a very decent valuation of FTRE.
98.18% of the companies in the same industry are more expensive than FTRE, based on the Price/Forward Earnings ratio.
FTRE's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.86.
Industry RankSector Rank
PE 16.34
Fwd PE 10.97
FTRE Price Earnings VS Forward Price EarningsFTRE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

FTRE's Enterprise Value to EBITDA is on the same level as the industry average.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 251.4
FTRE Per share dataFTRE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20 30

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as FTRE's earnings are expected to grow with 53.01% in the coming years.
PEG (NY)0.24
PEG (5Y)N/A
EPS Next 2Y64.76%
EPS Next 3Y53.01%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for FTRE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FORTREA HOLDINGS INC

NASDAQ:FTRE (9/19/2025, 6:44:39 PM)

After market: 10.13 0 (0%)

10.13

-0.52 (-4.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)08-06 2025-08-06/bmo
Earnings (Next)11-06 2025-11-06/bmo
Inst Owners98.83%
Inst Owner Change6.61%
Ins Owners0.22%
Ins Owner Change29.4%
Market Cap919.80M
Analysts53.75
Price Target7.8 (-23%)
Short Float %11.63%
Short Ratio5.46
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)162.11%
Min EPS beat(2)126.66%
Max EPS beat(2)197.56%
EPS beat(4)2
Avg EPS beat(4)65.68%
Min EPS beat(4)-51.68%
Max EPS beat(4)197.56%
EPS beat(8)3
Avg EPS beat(8)-57.12%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)7.8%
Min Revenue beat(2)4.96%
Max Revenue beat(2)10.63%
Revenue beat(4)2
Avg Revenue beat(4)2.7%
Min Revenue beat(4)-2.83%
Max Revenue beat(4)10.63%
Revenue beat(8)3
Avg Revenue beat(8)-1.24%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)25.93%
PT rev (3m)27.98%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-61.34%
EPS NY rev (1m)19.86%
EPS NY rev (3m)23.68%
Revenue NQ rev (1m)0.79%
Revenue NQ rev (3m)-5.61%
Revenue NY rev (1m)4.64%
Revenue NY rev (3m)4.76%
Valuation
Industry RankSector Rank
PE 16.34
Fwd PE 10.97
P/S 0.34
P/FCF N/A
P/OCF N/A
P/B 1.56
P/tB N/A
EV/EBITDA 251.4
EPS(TTM)0.62
EY6.12%
EPS(NY)0.92
Fwd EY9.11%
FCF(TTM)-1.14
FCFYN/A
OCF(TTM)-0.97
OCFYN/A
SpS30.1
BVpS6.49
TBVpS-11.35
PEG (NY)0.24
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -36.22%
ROE -174.29%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 19.73%
FCFM N/A
ROA(3y)-1.75%
ROA(5y)-2.26%
ROE(3y)-6.6%
ROE(5y)-5.54%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.07%
GM growth 5YN/A
F-Score3
Asset Turnover0.96
Health
Industry RankSector Rank
Debt/Equity 1.87
Debt/FCF N/A
Debt/EBITDA 134.26
Cap/Depr 18.99%
Cap/Sales 0.56%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.02
Quick Ratio 1.02
Altman-Z 0.49
F-Score3
WACC10.14%
ROIC/WACCN/A
Cap/Depr(3y)43.05%
Cap/Depr(5y)33.05%
Cap/Sales(3y)1.37%
Cap/Sales(5y)1.18%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)72.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%733.33%
EPS Next Y68.93%
EPS Next 2Y64.76%
EPS Next 3Y53.01%
EPS Next 5Y42.19%
Revenue 1Y (TTM)-4.96%
Revenue growth 3Y-4.1%
Revenue growth 5YN/A
Sales Q2Q%7.23%
Revenue Next Year-2.61%
Revenue Next 2Y-1.44%
Revenue Next 3Y0%
Revenue Next 5Y1.53%
EBIT growth 1Y-39.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-3.09%
EBIT Next 3Y8.59%
EBIT Next 5Y11.67%
FCF growth 1Y85.25%
FCF growth 3Y18.31%
FCF growth 5YN/A
OCF growth 1Y56.06%
OCF growth 3Y15.67%
OCF growth 5YN/A